Our study also showed that genetic reduction in RhoA expression or pharmacologic inhibition of RhoA activity reduced activation of the type I IFN pathway, supporting its potential a therapeutic target for the treatment of SLE. Here, RHOA is linked to systemic lupus erythematosus.